- Home
- PCB vs STRO Comparison
PCB vs STRO Comparison
Compare PCB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- STRO
- Stock Information
- Founded
- PCB 2003
- STRO 2003
- Country
- PCB United States
- STRO United States
- Employees
- PCB N/A
- STRO N/A
- Industry
- PCB Major Banks
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCB Finance
- STRO Health Care
- Exchange
- PCB Nasdaq
- STRO Nasdaq
- Market Cap
- PCB 295.7M
- STRO 292.6M
- IPO Year
- PCB N/A
- STRO 2018
- Fundamental
- Price
- PCB $21.85
- STRO $2.84
- Analyst Decision
- PCB Hold
- STRO Strong Buy
- Analyst Count
- PCB 2
- STRO 7
- Target Price
- PCB $22.00
- STRO $12.14
- AVG Volume (30 Days)
- PCB 44.0K
- STRO 921.2K
- Earning Date
- PCB 01-23-2025
- STRO 11-13-2024
- Dividend Yield
- PCB 3.32%
- STRO N/A
- EPS Growth
- PCB N/A
- STRO N/A
- EPS
- PCB 1.68
- STRO N/A
- Revenue
- PCB $94,833,000.00
- STRO $160,955,000.00
- Revenue This Year
- PCB N/A
- STRO N/A
- Revenue Next Year
- PCB $10.34
- STRO N/A
- P/E Ratio
- PCB $12.92
- STRO N/A
- Revenue Growth
- PCB N/A
- STRO 230.90
- 52 Week Low
- PCB $14.50
- STRO $2.45
- 52 Week High
- PCB $21.91
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- PCB 68.05
- STRO 40.85
- Support Level
- PCB $20.93
- STRO $2.66
- Resistance Level
- PCB $21.62
- STRO $2.86
- Average True Range (ATR)
- PCB 0.52
- STRO 0.25
- MACD
- PCB -0.00
- STRO -0.01
- Stochastic Oscillator
- PCB 96.18
- STRO 24.22
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.